Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives

Backhaus, Philipp; Noto, Benjamin; Avramović, Nemanja; Grubert, Lena Sophie; Huss, Sebastian; Bögemann, Martin; Stegger, Lars; Weckesser, Matthias; Schäfers, Michael; Rahbar, Kambiz

doi:10.1007/s00259-017-3922-y

Cited by 129 publications

(145 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Areas in the whole body having uptake above the background activity were de ned as metastatic. Typical pitfalls such as PSMA uptake in sacral and coeliac ganglia or in the stellate ganglia were frequently observed but were not considered pathological [20]. This interpretation criterion comes from the result of our clinical experience and consistent with published literature [21][22][23][24].…”

Section: Image Analysissupporting

confidence: 72%

The Value of 18F-PSMA-1007 PET/CT in Identifying High-Risk Prostate Cancer

Hong¹,

Liu²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Clinical management decisions on prostate cancer (PCa) are often based on a determination of risk. 68Ga-prostate-specific membrane antigen (PSMA)-11-positron-emission-tomography (PET)/ computer-tomography (CT) is an attractive modality to assess biochemical recurrence of PCa, detect metastatic disease and stage of primary PCa, making it a promising strategy for risk stratification. However, due to some limitation of 68Ga-PSMA-11 the development of alternative tracers is of high interest. In this study, we aimed to investigate the value of the new PET trace 18F-PSMA-1007 in identifying high-risk PCa.Methods: 170 patients with primary PCa underwent 18F-PSMA-1007 PET/CT were retrospectively analyzed. According to the European Association of Urology (EAU) guidelines on prostate cancer for PCa, patients were classified into low-intermediate-risk (LMR) group or high-risk (HR) group. The maximum standardized uptake values (SUVmax) of the primary prostate tumor was measured on PET/CT images. The diagnostic performance of PET/CT for LMR and HR PCa were calculated and the relationship between the SUVmax of primary prostate tumor, prostate-specific antigen (PSA) level and Gleason score (GS) were analyzed.Results: Of all 170 patients, 55 patients were classified into LMR group and 115 patients were classified into HR group. There was a significant positive correlation between the PSA level/GS and SUVmax (r = 0.597, r = 0.446, P < 0.001, respectively). Tumors with GS of 6 and 7a showed significantly lower 18F-PSMA-1007 uptake compared to patients with GS of 8, 9, and 10 (P < 0.001). SUVmax in patients of HR was significantly higher than those of LMR (median SUVmax: 20.20 versus 8.40; P < 0.001). In receiver operating characteristic (ROC) curve analysis, the optimal cutoff value of the SUVmax for identifying high-risk PCa was set as 10.78 (area under the curve [AUC]: 0.873; sensitivity: 90.4%; specificity: 69.1%). Conclusion: 18F-PSMA-1007 PET/CT showed the powerful diagnosis efficacy for high-risk PCa, which can be used as an objective imaging reference index for clinical reference.

show abstract

Section: Image Analysissupporting

confidence: 72%

The Value of 18F-PSMA-1007 PET/CT in Identifying High-Risk Prostate Cancer

Hong¹,

Liu²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…This study provides further evidence that prostatespecific membrane antigen (PSMA) is not at all prostatespecific but widely expressed in solid tumors including also hepatocellular carcinoma, which opens up new diagnostic and therapeutic possibilities [1,11]. Although many tumor types express PSMA to certain extent [2][3][4][5], the applicability of PSMA as a diagnostic or therapeutic target will probably be limited to those which show a higher than average expression (see analysis of mRNA expression based on TCGA expression data on Figure 1).…”

Section: Discussionmentioning

confidence: 84%

“…The prostate-specific membrane antigen (PSMA) is currently being established as a potent diagnostic marker in many tumor types [1]. Many normal tissue types (kidney, liver, salivary and lacrimal glands, breast and prostate tissue) and tumor entities other than prostate cancer express PSMA, mostly on endothelial cells of tumor vessels [2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging

Tolkach

Goltz

Kremer

et al. 2019

35. Jahrestagung Der Deutschen Arbeitsgemeinschaft Zum Studium Der Leber

View full text Add to dashboard Cite

“…Although it is not effective in demonstrating primary tumor due to renal excretion, it is an agent that can be useful in the characterization of lesions that are considered as suspicious by conventional methods (25). Higher uptake is observed in clear cell carcinoma than in papillary type (26,27). In the literature, the data on this subject consisted of case reports and case series, and the sensitivity and positive predictive value of Ga-68 Prostate-specific membrane antigen (PSMA) PET/CT were better compared to CT (92% vs 69% and 97% vs 80%) (28).…”

Section: Ga-68 Prostate-specific Membrane Antigen Pet/ctmentioning

confidence: 99%

Nuclear Medicine Applications in Diagnosis of Urological Tumors

Araz¹,

Ürün²

2019

uob

View full text Add to dashboard Cite

Except for prostate carcinoma, there is limited data in the literature on the role of nuclear imaging methods in the management of urological cancers. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is generally the most widely used method in oncological imaging. However, the diagnostic power of this radiopharmaceutical in urological tumors is weakened partially due to its physiological urinary excretion. For this reason, some other 18F-labeled molecules, especially Ga-68 prostate-specific membrane antigen for prostate cancer and 18F-sodium fluoride for bone metastases, have recently gained importance. In addition, characterization of renal masses with Tc-99m methoxy isobutyl isonitrile (MIBI), a nonspecific tumor agent, and detection of bone metastases with whole-body Tc-99m methylene diphosphonate (MDP) bone scintigraphy are still used. In this review, scintigraphic methods and PET/CT imaging used in diagnosis and follow-up of urological tumors will be discussed.

show abstract

Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives

Abstract: The non-exclusivity of PSMA in prostate cancer opens a window to utilize the spectrum of available radioactive PSMA ligands for imaging and molecular characterization and maybe even therapy of non-prostate disease.

Cited by 129 publications

References 167 publications

The Value of 18F-PSMA-1007 PET/CT in Identifying High-Risk Prostate Cancer

The Value of 18F-PSMA-1007 PET/CT in Identifying High-Risk Prostate Cancer

Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging

Nuclear Medicine Applications in Diagnosis of Urological Tumors

Contact Info

Product

Resources

About